Parsec Financial Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | $13M | Buy |
81,583
+1,090
| +1% | +$167K | 0.55% | 48 |
|
|
2022
Q4 | $13M | Sell |
80,493
-1,979
| -2% | -$303K | 0.58% | 51 |
|
|
2022
Q3 | $11.1M | Sell |
82,472
-3,715
| -4% | -$533K | 0.55% | 51 |
|
|
2022
Q2 | $13.2M | Buy |
86,187
+2,939
| +4% | +$449K | 0.64% | 43 |
|
|
2022
Q1 | $13.5M | Buy |
83,248
+12,244
| +17% | +$1.78M | 0.57% | 46 |
|
|
2021
Q4 | $9.61M | Buy |
71,004
+7,078
| +11% | +$836K | 0.4% | 57 |
|
|
2021
Q3 | $7.39M | Buy |
63,926
+10,132
| +19% | +$1.16M | 0.31% | 63 |
|
|
2021
Q2 | $6.06M | Buy |
53,794
+17,335
| +48% | +$1.95M | 0.29% | 67 |
|
|
2021
Q1 | $3.95M | Buy |
36,459
+24,959
| +217% | +$2.67M | 0.2% | 85 |
|
|
2020
Q4 | $1.23M | Buy |
11,500
+1,273
| +12% | +$122K | 0.07% | 132 |
|
|
2020
Q3 | $896K | Sell |
10,227
-315
| -3% | -$29.7K | 0.05% | 135 |
|
|
2020
Q2 | $1.03M | Sell |
10,542
-1,057
| -9% | -$93.1K | 0.07% | 131 |
|
|
2020
Q1 | $884K | Sell |
11,599
-1,591
| -12% | -$136K | 0.07% | 129 |
|
|
2019
Q4 | $1.17M | Buy |
13,190
+501
| +4% | +$41.6K | 0.07% | 129 |
|
|
2019
Q3 | $961K | Sell |
12,689
-3,814
| -23% | -$261K | 0.06% | 133 |
|
|
2019
Q2 | $1.2M | Buy |
16,503
+3,895
| +31% | +$306K | 0.07% | 129 |
|
|
2019
Q1 | $1.02M | Buy |
12,608
+1,147
| +10% | +$93.8K | 0.06% | 140 |
|
|
2018
Q4 | $1.06M | Buy |
11,461
+4,696
| +69% | +$413K | 0.08% | 139 |
|
|
2018
Q3 | $640K | Buy |
6,765
+725
| +12% | +$68.8K | 0.04% | 162 |
|
|
2018
Q2 | $560K | Sell |
6,040
-165
| -3% | -$16.1K | 0.04% | 163 |
|
|
2018
Q1 | $587K | Sell |
6,205
-13,701
| -69% | -$1.51M | 0.04% | 166 |
|
|
2017
Q4 | $1.93M | Sell |
19,906
-975
| -5% | -$91.9K | 0.13% | 122 |
|
|
2017
Q3 | $1.86M | Buy |
20,881
+15,165
| +265% | +$1.15M | 0.13% | 121 |
|
|
2017
Q2 | $414K | Buy |
5,716
+167
| +3% | +$11.2K | 0.03% | 158 |
|
|
2017
Q1 | $362K | Sell |
5,549
-2,457
| -31% | -$154K | 0.03% | 158 |
|
|
2016
Q4 | $501K | Buy |
8,006
+94
| +1% | +$5.74K | 0.04% | 142 |
|
|
2016
Q3 | $499K | Buy |
7,912
+768
| +11% | +$49.7K | 0.05% | 141 |
|
|
2016
Q2 | $442K | Buy |
7,144
+251
| +4% | +$15.3K | 0.04% | 141 |
|
|
2016
Q1 | $394K | Buy |
6,893
+767
| +13% | +$42.8K | 0.04% | 142 |
|
|
2015
Q4 | $363K | Buy |
6,126
+227
| +4% | +$13.1K | 0.04% | 143 |
|
|
2015
Q3 | $321K | Sell |
5,899
-183
| -3% | -$11.9K | 0.04% | 145 |
|
|
2015
Q2 | $409K | Sell |
6,082
-203
| -3% | -$13.3K | 0.04% | 140 |
|
|
2015
Q1 | $368K | Buy |
6,285
+180
| +3% | +$10.9K | 0.04% | 144 |
|
|
2014
Q4 | $400K | Buy |
6,105
+32
| +0.5% | +$2.02K | 0.04% | 126 |
|
|
2014
Q3 | $351K | Sell |
6,073
-395
| -6% | -$21.9K | 0.04% | 130 |
|
|
2014
Q2 | $365K | Sell |
6,468
-250
| -4% | -$13.1K | 0.04% | 127 |
|
|
2014
Q1 | $345K | Sell |
6,718
-150
| -2% | -$7.58K | 0.04% | 124 |
|
|
2013
Q4 | $363K | Buy |
6,868
+1,319
| +24% | +$64.8K | 0.04% | 116 |
|
|
2013
Q3 | $248K | Buy |
+5,549
| New | +$246K | 0.03% | 121 |
|
Other funds holding ABBV
Parsec Financial Management's ABBV Position: Q1 2023 in Review
Parsec Financial Management increased its AbbVie (ABBV) stake by 1.4% in Q1 2023, buying an estimated $167K and bringing the position to 81,583 shares worth $13M. The position accounts for 0.55% of the portfolio, ranked #48.
Parsec Financial Management first reported a position in ABBV in Q3 2013 and has held it in 39 quarters since. The position peaked at $13.5M in Q1 2022. 3,138 funds tracked by Wall St. Rank hold ABBV as of Q1 2023.
- Parsec Financial Management held 81,583 shares of AbbVie worth $13M as of Q1 2023.
- Parsec Financial Management bought 1,090 AbbVie shares in Q1 2023, an estimated $167K.
- AbbVie made up 0.55% of Parsec Financial Management's portfolio in Q1 2023, its #48 holding.
- Parsec Financial Management first reported a position in AbbVie in Q3 2013 and has held it in 39 quarters since.
- Parsec Financial Management's AbbVie position peaked at $13.5M in Q1 2022.
- 3,138 funds tracked by Wall St. Rank held AbbVie as of Q1 2023.
Based on Parsec Financial Management's 13F filing for Q1 2023, filed 6 Apr 2023.